🎉 M&A multiples are live!
Check it out!

Vertex Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vertex Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Armata Pharmaceuticals, and Pharming.

Vertex Pharmaceuticals Overview

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.


Founded

1989

HQ

United States of America
Employees

6.1K+

Website

vrtx.com

Financials

LTM Revenue $11.2B

LTM EBITDA $1.9B

EV

$125B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals has a last 12-month revenue of $11.2B and a last 12-month EBITDA of $1.9B.

In the most recent fiscal year, Vertex Pharmaceuticals achieved revenue of $11.0B and an EBITDA of $486M.

Vertex Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vertex Pharmaceuticals valuation multiples based on analyst estimates

Vertex Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $9.9B $11.0B XXX XXX XXX
Gross Profit $7.9B $8.6B XXX XXX XXX
Gross Margin 80% 78% XXX XXX XXX
EBITDA $4.6B $486M XXX XXX XXX
EBITDA Margin 47% 4% XXX XXX XXX
Net Profit $3.3B $3.6B XXX XXX XXX
Net Margin 34% 33% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vertex Pharmaceuticals Stock Performance

As of March 17, 2025, Vertex Pharmaceuticals's stock price is $505.

Vertex Pharmaceuticals has current market cap of $130B, and EV of $125B.

See Vertex Pharmaceuticals trading valuation data

Vertex Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$125B $130B XXX XXX XXX XXX $4.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vertex Pharmaceuticals Valuation Multiples

As of March 17, 2025, Vertex Pharmaceuticals has market cap of $130B and EV of $125B.

Vertex Pharmaceuticals's trades at 11.2x LTM EV/Revenue multiple, and 66.4x LTM EBITDA.

Analysts estimate Vertex Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vertex Pharmaceuticals and 10K+ public comps

Vertex Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $125B XXX XXX XXX
EV/Revenue 11.4x XXX XXX XXX
EV/EBITDA 257.6x XXX XXX XXX
P/E -242.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -128.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vertex Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vertex Pharmaceuticals Valuation Multiples

Vertex Pharmaceuticals's NTM/LTM revenue growth is 9%

Vertex Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.8M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Vertex Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vertex Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vertex Pharmaceuticals and other 10K+ public comps

Vertex Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 12% XXX XXX XXX XXX
EBITDA Margin 4% XXX XXX XXX XXX
EBITDA Growth -89% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 13% XXX XXX XXX XXX
Revenue per Employee $1.8M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 33% XXX XXX XXX XXX
Opex to Revenue 46% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vertex Pharmaceuticals Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vertex Pharmaceuticals M&A and Investment Activity

Vertex Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Vertex Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vertex Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vertex Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vertex Pharmaceuticals

When was Vertex Pharmaceuticals founded? Vertex Pharmaceuticals was founded in 1989.
Where is Vertex Pharmaceuticals headquartered? Vertex Pharmaceuticals is headquartered in United States of America.
How many employees does Vertex Pharmaceuticals have? As of today, Vertex Pharmaceuticals has 6.1K+ employees.
Who is the CEO of Vertex Pharmaceuticals? Vertex Pharmaceuticals's CEO is Dr. Reshma Kewalramani, M.D..
Is Vertex Pharmaceuticals publicy listed? Yes, Vertex Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Vertex Pharmaceuticals? Vertex Pharmaceuticals trades under VRTX ticker.
When did Vertex Pharmaceuticals go public? Vertex Pharmaceuticals went public in 1991.
Who are competitors of Vertex Pharmaceuticals? Similar companies to Vertex Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Vertex Pharmaceuticals? Vertex Pharmaceuticals's current market cap is $130B
What is the current revenue of Vertex Pharmaceuticals? Vertex Pharmaceuticals's last 12-month revenue is $11.2B.
What is the current EBITDA of Vertex Pharmaceuticals? Vertex Pharmaceuticals's last 12-month EBITDA is $1.9B.
What is the current EV/Revenue multiple of Vertex Pharmaceuticals? Current revenue multiple of Vertex Pharmaceuticals is 11.2x.
What is the current EV/EBITDA multiple of Vertex Pharmaceuticals? Current EBITDA multiple of Vertex Pharmaceuticals is 66.4x.
What is the current revenue growth of Vertex Pharmaceuticals? Vertex Pharmaceuticals revenue growth between 2023 and 2024 was 12%.
Is Vertex Pharmaceuticals profitable? Yes, Vertex Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.